Austin Health

Title
Music medicine to improve the tolerability of onabotulinumtoxinA injections for chronic migraine: an open-label prospective cohort study.
Publication Date
2023
Author(s)
Ray, Jason C
Raviskanthan, Subahari
Subject
BOTULINUM TOXIN
MIGRAINE
Type of document
Journal Article
OrcId
0000-0003-4833-5507
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1136/bmjno-2023-000492
Abstract
OnabotulinumtoxinA for migraine involves 31 injected repeated every 12 weeks. Tolerability is a significant factor impacting discontinuation. Music medicine has not been studied previously as an intervention to improve the tolerability of injections. A single-centre prospective cohort study was undertaken. Following baseline, patients had music played during the procedure. Change in Visual Analogue Score (VAS) was assessed as the primary outcome. Over 6 months, 50 patients were recruited with a median age of 42, and median duration of therapy of 13.5 months. 'Quiet calm classical music' was associated with a significant reduction in VAS (z=-4.7, p<0.001). Duration of therapy, disease state or headache frequency had no correlation with change in VAS. Music medicine is associated with a significant reduction in the procedural pain of onabotulinumtoxinA injections in prospective study. Further study is required to explore other modifiable factors to improve patient experience.
Link
Citation
BMJ Neurology Open 2023; 5(2)
Jornal Title
BMJ Neurology Open
ISSN
2632-6140

Files:

NameSizeformatDescriptionLink